Microcytosis in agnogenic myeloid metaplasia: Prevalence and clinical correlates

被引:7
|
作者
Tefferi, A
Dingli, D
Li, CY
Mesa, RA
机构
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
[2] Mayo Clin, Div Hematopatol, Rochester, MN 55905 USA
关键词
myelofibrosis; microcytosis; prognosis; incidence; survival;
D O I
10.1016/j.leukres.2005.10.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Microcytosis is a characteristic laboratory feature for both iron deficiency anemia and thalassemia. It is also infrequently seen in "anemia of chronic disease" that accompanies a spectrum of chronic conditions including rheumatoid arthritis, polymyalgia rheumatica, diabetes mellitus, connective tissue disease, and protracted infection. In addition, there is a well established but pathogenetically obscure association of microcytosis with Hodgkin's lymphoma, Castleman's disease, and renal cell carcinoma. In the current study, we show that microcytosis is a frequent laboratory feature in agnogenic myeloid metaplasia and investigate its clinical relevance in the particular setting., (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:677 / 680
页数:4
相关论文
共 50 条
  • [21] Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia
    Elliott, MA
    Yoon, SY
    Kao, P
    Li, CY
    Tefferi, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 68 (03) : 175 - 179
  • [22] Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County study, 1976-1995
    Mesa, RA
    Silverstein, MN
    Jacobsen, SJ
    Wollan, PC
    Tefferi, A
    AMERICAN JOURNAL OF HEMATOLOGY, 1999, 61 (01) : 10 - 15
  • [23] Thalidomide therapy for myelofibrosis with myeloid metaplasia
    Thomas, DA
    Giles, FJ
    Albitar, M
    Cortes, JE
    Verstovsek, S
    Faderl, S
    O'Brien, SM
    Garcia-Manero, G
    Keating, MJ
    Pierce, S
    Zeldis, J
    Kantarjian, HM
    CANCER, 2006, 106 (09) : 1974 - 1984
  • [24] The role of splenectomy in myelofibrosis with myeloid metaplasia
    Barugola, G.
    Cavallini, A.
    Lipari, G.
    Armatura, G.
    Mantovani, W.
    Baggio, E.
    MINERVA CHIRURGICA, 2010, 65 (06) : 619 - 625
  • [25] Chronic bone pain: Myeloid metaplasia
    Raffray, Loic
    Dieval, Celine
    Viallard, Jean-Francois
    PRESSE MEDICALE, 2013, 42 (01): : 117 - 119
  • [26] Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia
    M. C. Le Bousse-Kerdilès
    M. C. Martyré
    Springer Seminars in Immunopathology, 2000, 21 (4): : 491 - 508
  • [27] Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study
    Piccaluga, PP
    Visani, G
    Pileri, SA
    Ascani, S
    Grafone, T
    Isidori, A
    Malagola, M
    Finelli, C
    Martinelli, G
    Ricci, P
    Baccarani, M
    Tura, S
    LEUKEMIA, 2002, 16 (09) : 1609 - 1614
  • [28] Palliative splenectomy in myelofibrosis with myeloid metaplasia
    Mesa, RA
    Tefferi, A
    LEUKEMIA & LYMPHOMA, 2001, 42 (05) : 901 - 911
  • [29] The forgotten myeloproliferative disorder: Myeloid metaplasia
    Tefferi, A
    ONCOLOGIST, 2003, 8 (03) : 225 - 231
  • [30] Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications
    Gangat, Naseema
    Wolanskyj, Alexandra P.
    Tefferi, Ayalew
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (04) : 327 - 333